查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1553622

卵巢症候群治療市場規模、佔有率和趨勢分析報告：按藥物類別、手術、分銷管道、地區和細分市場預測，2024-2030年

Polycystic Ovarian Syndrome Treatment Market Size, Share & Trends Analysis Report By Drug Class (Oral Contraceptives, Antiandrogens), By Surgery, By Distribution Channel, By Region, And Segment Forecasts, 2024 - 2030
出版日期: | 出版商: Grand View Research | 英文 100 Pages | 商品交期: 2-10個工作天內

價格
簡介目錄

多囊性卵巢治療市場的成長與趨勢：

Grand View Research, Inc.最新報告顯示，到2030年，全球卵巢囊性卵巢症候群治療市場規模將達到69.9億美元，2024年至2030年複合年成長率為6.5%。

根據美國疾病管制與預防中心 (CDC) 的數據，美國卵巢(PCOS) 是女性不孕症的最常見原因。在美國，大約 6% 至 12% 的育齡女性患有 PCOS。此外，隨著病情的進展，會出現代謝異常，如果延遲治療，可能會發展為第2型糖尿病。此疾病的嚴重程度會增加患者罹患子宮內膜癌的風險。因此，早期診斷和有效治療對於復健非常重要。

目前，市面上還沒有針對這種疾病的特效藥物。因此，治療症狀是治療方法的首要目標。由於與此症候群相關的症狀多種多樣，因此使用不同的藥物類別/組合進行治療。因此，新興市場領導者專注於開拓特定藥物/治療方法來治療這種疾病的根本原因。Astra Zeneca是參與開發此類藥物的領導者之一。

多囊性卵巢治療市場報告亮點

  • 多囊性卵巢症候群盛行率的持續上升主要推動了全球該市場的成長。
  • 政府機構和市場相關人員正在努力提高女性對多囊性卵巢症候群早期診斷的好處和現有治療方法的認知，從而推動了市場的發展。
  • 多囊性卵巢症候群的治療主要包括生活方式的改變，如均衡飲食和鍛煉，以及口服避孕藥、抗雄激素、胰島素增敏劑、抗肥胖藥物和抗憂鬱症等藥物治療。
  • 如果藥物治療對病情沒有反應，則首選手術治療，例如卵巢楔形切除術或腹腔鏡卵巢打孔術。
  • 胰島素增敏劑在市場上佔據主導地位，因為它們被廣泛用於治療胰島素抗性以預防糖尿病（一種與多囊性卵巢症候群相關的風險）。
  • 口服避孕藥（OCP）領域預計將以最快的速度成長，其次是用於治療多毛症和痤瘡等症狀性疾病的抗雄激素藥物。
  • 北美佔據市場主導地位，其次是歐洲。該地區的高市場佔有率得益於其高知名度和先進的醫療設施。
  • 政府加強提高人們對多囊性卵巢症候群症狀、診斷和可用治療方法的認知，導致該地區被診斷出患有此症候群的女性人數不斷增加。
  • 中國是利潤最豐厚的市場之一，由於中國有大量患有多囊性卵巢症候群的肥胖女性，因此為全球和本土公司提供了巨大的成長機會。

目錄

第1章調查方法和範圍

第 2 章執行摘要

第3章多囊性卵巢治療市場變數、趨勢與範圍

  • 市場介紹/系統展望
  • 市場規模及成長前景
  • 市場動態
    • 市場促進因素分析
    • 市場限制因素分析
  • 多囊性卵巢治療市場分析工具
    • 波特的分析
    • PESTEL分析

第4章多囊性卵巢治療市場：依藥物類別估算與趨勢分析

  • 細分儀表板
  • 多囊性卵巢治療市場：2023 年和 2030 年按藥物類別的變化分析
  • 口服避孕藥
  • 抗雄激素
  • 胰島素增敏劑
  • 抗憂鬱症
  • 預防肥胖

第5章多囊性卵巢卵巢治療市場：手術估計與趨勢分析

  • 細分儀表板
  • 多囊性卵巢治療市場：2023 年和 2030 年手術變化分析
  • 卵巢楔形切除術
  • 腹腔鏡卵巢穿孔

第6章多囊性卵巢治療市場：按分銷管道估計和趨勢分析

  • 細分儀表板
  • 多囊性卵巢治療市場：2023 年和 2030 年分銷管道變化分析
  • 醫院藥房
  • 藥局和零售藥局
  • 線上提供者

第7章多囊性卵巢卵巢治療市場：區域估計與趨勢分析

  • 2023 年及 2030 年多卵巢治療市場佔有率（按地區）
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 英國
    • 德國
    • 法國
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳洲
  • 拉丁美洲
    • 巴西
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第8章 競爭格局

  • 主要市場參與企業的最新趨勢和影響分析
  • 公司分類
  • 企業熱力圖分析
  • 公司簡介
    • AstraZeneca
    • Bayer AG
    • Merck KGaA.
    • Abbott
    • Pfizer, Inc
    • Sanofi
    • Bristol Myers Squibb Company
    • Teva Pharmaceutical Industries Ltd
    • Novartis AG
    • Ferring BV
簡介目錄
Product Code: GVR-2-68038-203-7

Polycystic Ovarian Syndrome Treatment Market Growth & Trends:

The global polycystic ovarian syndrome treatment market size is expected to reach USD 6.99 billion by 2030, registering a CAGR of 6.5% from 2024 to 2030, according to a new report by Grand View Research, Inc. According to the Centers of Disease Control & Prevention (CDC), Polycystic Ovary Syndrome (PCOS) is the most common cause of female infertility. Approximately 6% to 12% women of reproductive age suffer from PCOS in the U. S. Moreover, progression of this condition can lead to metabolic abnormalities, which may result in development of type 2 diabetes, if the syndrome is not treated on time. The severity of the disorder increases the risk of developing uterine and endometrial cancers in patients. Thus, early diagnosis and effective treatment are significant for successful recovery.

Presently, no specific drug is commercially available for this condition. Thus, treating symptoms is the prime aim of the treatment regimen. Owing to the various symptoms associated with this syndrome, a range of drug class/combinations is used in the treatment. Therefore, market leaders are focusing on developing a specific drug/treatment to cure the root cause of this disease. AstraZeneca is one of the leaders involved in developing such a drug.

Polycystic Ovarian Syndrome Treatment Market Report Highlights:

  • Constantly rising prevalence of PCOS is primarily driving the growth of this market across the globe
  • Initiatives undertaken by government bodies and market players to create awareness about benefits of early diagnosis and commercially available treatment for PCOS among women is boosting the market
  • Treatment of PCOS mainly includes lifestyle modification through balanced diet, exercise, and drugs such as oral contraceptives, antiandrogens, insulin-sensitizing agents, anti-obesity agents, and antidepressants
  • Surgical procedures such as ovarian wedge resection and laparoscopic ovarian drilling are preferred when patients do not respond to drug therapy
  • Insulin-sensitizing agents segment is dominating the market since these drugs are widely used for treatment of insulin resistance to prevent diabetes, which is a risk associated with PCOS
  • Oral Contraceptive Pills (OCPs) segment is expected to grow at the fastest rate followed by antiandrogen agents that are used for treating symptomatic conditions such as hirsutism and acne
  • North America is dominating the market followed by Europe. High awareness and availability of advanced healthcare facilities are factors responsible for the dominant share held by this region
  • Asia Pacific is expected to be the fastest growing region over the forecast period.Increasing government initiatives for raising awareness about symptoms & diagnosis of PCOS and available treatment are increasing the number of women being diagnosed with this syndrome in the region
  • China is one of the most lucrative markets with tremendous growth opportunities for global as well as local players owing to presence of a large pool of obese female population, which is at high risk of PCOS

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Market Definitions
  • 1.3. Research Methodology
    • 1.3.1. Information Procurement
    • 1.3.2. Information or Data Analysis
    • 1.3.3. Market Formulation & Data Visualization
    • 1.3.4. Data Validation & Publishing
  • 1.4. Research Scope and Assumptions
    • 1.4.1. List of Data Sources

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Insights

Chapter 3. Polycystic Ovarian Syndrome Treatment Market Variables, Trends, & Scope

  • 3.1. Market Introduction/Lineage Outlook
  • 3.2. Market Size and Growth Prospects (USD Billion)
  • 3.3. Market Dynamics
    • 3.3.1. Market Drivers Analysis
    • 3.3.2. Market Restraints Analysis
  • 3.4. Polycystic Ovarian Syndrome Treatment Market Analysis Tools
    • 3.4.1. Porter's Analysis
      • 3.4.1.1. Bargaining power of the suppliers
      • 3.4.1.2. Bargaining power of the buyers
      • 3.4.1.3. Threats of substitution
      • 3.4.1.4. Threats from new entrants
      • 3.4.1.5. Competitive rivalry
    • 3.4.2. PESTEL Analysis
      • 3.4.2.1. Political landscape
      • 3.4.2.2. Economic and Social landscape
      • 3.4.2.3. Technological landscape
      • 3.4.2.4. Environmental landscape
      • 3.4.2.5. Legal landscape

Chapter 4. Polycystic Ovarian Syndrome Treatment Market: Drug Class Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. Polycystic Ovarian Syndrome Treatment Market: Drug Class Movement Analysis, 2023 & 2030 (USD Billion)
  • 4.3. Oral Contraceptives
    • 4.3.1. Oral Contraceptives Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 4.4. Antiandrogens
    • 4.4.1. Antiandrogens Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 4.5. Insulin-sensitizing Agent
    • 4.5.1. Insulin-sensitizing Agent Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 4.6. Antidepressant
    • 4.6.1. Antidepressant Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 4.7. Anti-obesity
    • 4.7.1. Anti-obesity Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)

Chapter 5. Polycystic Ovarian Syndrome Treatment Market: Surgery Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. Polycystic Ovarian Syndrome Treatment Market: Surgery Movement Analysis, 2023 & 2030 (USD Billion)
  • 5.3. Ovarian Wedge Resection
    • 5.3.1. Ovarian Wedge Resection Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 5.4. Laparoscopic Ovarian Drilling
    • 5.4.1. Laparoscopic Ovarian Drilling Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)

Chapter 6. Polycystic Ovarian Syndrome Treatment Market: Distribution Channel Estimates & Trend Analysis

  • 6.1. Segment Dashboard
  • 6.2. Polycystic Ovarian Syndrome Treatment Market: Distribution Channel Movement Analysis, 2023 & 2030 (USD Billion)
  • 6.3. Hospital Pharmacy
    • 6.3.1. Hospital Pharmacy Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 6.4. Drug Store & Retail Pharmacy
    • 6.4.1. Drug Store & Retail Pharmacy Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 6.5. Online Providers
    • 6.5.1. Online Providers Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)

Chapter 7. Polycystic Ovarian Syndrome Treatment Market: Regional Estimates & Trend Analysis

  • 7.1. Polycystic Ovarian Syndrome Treatment Market Share, By Region, 2023 & 2030 (USD Billion)
  • 7.2. North America
    • 7.2.1. North America Polycystic Ovarian Syndrome Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.2.2. U.S.
    • 7.2.3. U.S. Polycystic Ovarian Syndrome Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.2.4. Canada
      • 7.2.4.1. Canada Polycystic Ovarian Syndrome Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.2.5. Mexico
      • 7.2.5.1. Mexico Polycystic Ovarian Syndrome Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 7.3. Europe
    • 7.3.1. Europe Polycystic Ovarian Syndrome Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.3.2. UK
      • 7.3.2.1. UK Polycystic Ovarian Syndrome Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.3.3. Germany
      • 7.3.3.1. Germany Polycystic Ovarian Syndrome Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.3.4. France
      • 7.3.4.1. France Polycystic Ovarian Syndrome Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 7.4. Asia Pacific
    • 7.4.1. Asia Pacific Polycystic Ovarian Syndrome Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.4.2. China
      • 7.4.2.1. China Polycystic Ovarian Syndrome Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.4.3. Japan
      • 7.4.3.1. Japan Polycystic Ovarian Syndrome Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.4.4. India
      • 7.4.4.1. India Polycystic Ovarian Syndrome Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.4.5. South Korea
      • 7.4.5.1. South Korea Polycystic Ovarian Syndrome Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.4.6. Australia
      • 7.4.6.1. Australia Polycystic Ovarian Syndrome Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 7.5. Latin America
    • 7.5.1. Latin America Polycystic Ovarian Syndrome Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.5.2. Brazil
      • 7.5.2.1. Brazil Polycystic Ovarian Syndrome Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 7.6. Middle East and Africa
    • 7.6.1. Middle East and Africa Polycystic Ovarian Syndrome Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.6.2. Saudi Arabia
      • 7.6.2.1. Saudi Arabia Polycystic Ovarian Syndrome Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.6.3. UAE
      • 7.6.3.1. UAE Polycystic Ovarian Syndrome Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.6.4. South Africa
      • 7.6.4.1. South Africa Polycystic Ovarian Syndrome Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)

Chapter 8. Competitive Landscape

  • 8.1. Recent Developments & Impact Analysis by Key Market Participants
  • 8.2. Company Categorization
  • 8.3. Company Heat Map Analysis
  • 8.4. Company Profiles
    • 8.4.1. AstraZeneca
      • 8.4.1.1. Participant's Overview
      • 8.4.1.2. Financial Performance
      • 8.4.1.3. Product Benchmarking
      • 8.4.1.4. Recent Developments/ Strategic Initiatives
    • 8.4.2. Bayer AG
      • 8.4.2.1. Participant's Overview
      • 8.4.2.2. Financial Performance
      • 8.4.2.3. Product Benchmarking
      • 8.4.2.4. Recent Developments/ Strategic Initiatives
    • 8.4.3. Merck KGaA.
      • 8.4.3.1. Participant's Overview
      • 8.4.3.2. Financial Performance
      • 8.4.3.3. Product Benchmarking
      • 8.4.3.4. Recent Developments/ Strategic Initiatives
    • 8.4.4. Abbott
      • 8.4.4.1. Participant's Overview
      • 8.4.4.2. Financial Performance
      • 8.4.4.3. Product Benchmarking
      • 8.4.4.4. Recent Developments/ Strategic Initiatives
    • 8.4.5. Pfizer, Inc
      • 8.4.5.1. Participant's Overview
      • 8.4.5.2. Financial Performance
      • 8.4.5.3. Product Benchmarking
      • 8.4.5.4. Recent Developments/ Strategic Initiatives
    • 8.4.6. Sanofi
      • 8.4.6.1. Participant's Overview
      • 8.4.6.2. Financial Performance
      • 8.4.6.3. Product Benchmarking
      • 8.4.6.4. Recent Developments/ Strategic Initiatives
    • 8.4.7. Bristol Myers Squibb Company
      • 8.4.7.1. Participant's Overview
      • 8.4.7.2. Financial Performance
      • 8.4.7.3. Product Benchmarking
      • 8.4.7.4. Recent Developments/ Strategic Initiatives
    • 8.4.8. Teva Pharmaceutical Industries Ltd
      • 8.4.8.1. Participant's Overview
      • 8.4.8.2. Financial Performance
      • 8.4.8.3. Product Benchmarking
      • 8.4.8.4. Recent Developments/ Strategic Initiatives
    • 8.4.9. Novartis AG
      • 8.4.9.1. Participant's Overview
      • 8.4.9.2. Financial Performance
      • 8.4.9.3. Product Benchmarking
      • 8.4.9.4. Recent Developments/ Strategic Initiatives
    • 8.4.10. Ferring B.V.
      • 8.4.10.1. Participant's Overview
      • 8.4.10.2. Financial Performance
      • 8.4.10.3. Product Benchmarking
      • 8.4.10.4. Recent Developments/ Strategic Initiatives